The 7 Best Expert-Approved Products for Keratosis Pilaris on Amazon's Prime Day Deals
Perfectly harmless but infinitely annoying, keratosis pilaris, or KP, plagues many of our limbs and stomachs, dotting them with raised red spots that seem to never go away. The condition has been affectionately (or not so affectionately) nicknamed 'strawberry skin' and 'chicken skin' because it resembles the bumpy surface of a strawberry or plucked fowl. Many folks out there accept their fate and live with it, but there's hope yet for those of us who wish to take up the fight against KP. An army of products exist on Amazon that can help eliminate—or at least reduce—keratosis pilaris.
If your strawberry skin has made you feel alone, it turns out that over 50 percent of the population share the same woe, says Dallas-based dermatologist Elizabeth Houshmand. 'It's a frustrating condition where keratin protein builds up around hair follicles and results in bumpy and rough patches of skin,' she explains. 'The reason for the buildup of keratin is unknown, but often occurs alongside other skin conditions such as dermatitis and eczema,' she adds.
But two major steps can eradicate KP: 'Gentle exfoliation can be helpful, along with moisturizing the skin,' Houshmand says. The key word here is gentle. If you use an exfoliator that's too harsh or scrub at your skin too often, you can wreak havoc on your moisture barrier and worsen things. We tried a few KP-eliminating products ourselves, consulted a dermatologist, and scrolled through thousands of Amazon reviews to locate the nine best products for KP, including body scrubs, body exfoliators, and body creams. Keep reading, and you'll be that much closer to smoother, calmer, and more hydrated skin.
Skincare TikTok is obsessed with this exfoliator for a reason. With glycolic and lactic acid, the scrub acts as both a physical and chemical exfoliator to make KP a thing of the past.
Key ingredients: Glycolic acid, lactic acid, pumice buffing beads
Amazon rating: 4.4/5 stars
An Amazon reviewer says: 'Honestly, I use this scrub all over my body, whether there's KP there or not. The product is genuinely one of the best body exfoliators I've ever used. I often get compliments on how soft my skin is, and my arms and legs are especially smooth to the touch when I'm consistent with the KP Bump Eraser. ' —Carol Lee, ELLE.com associate beauty e-commerce writer
Lactic acid is on the gentler side in terms of chemical exfoliators, but it works hard in this formula to loosen dead skin cells and get rid of those pesky bumps associated with strawberry skin. The cream is so rich that you can use it as your moisturizer, or you can follow up with a body cream or lotion if you need more hydration. Just make sure to apply it to dry skin because if your skin is still a little wet or damp, the formula can be difficult to spread.
Key ingredient: Lactic acid
Amazon rating: 4.2/5 stars
An ELLE editor says: 'The tube may be small, but I only needed a little to see results. Because my KP only exists on my upper arms, I applied a pea-sized amount to each arm after every shower and before applying my regular body moisturizer. Within just a few days, my arms felt smoother, and I saw that some of the more irritated spots had calmed down. I personally love how thick it is—even though the formula is exfoliating my skin, I don't feel like I'm stripping it of moisture.' —Carol Lee
Who said you can't exfoliate and hydrate at the same time? This super-thick shea body butter does it all; 10 percent AHA wipes away any signs of KP, while squalane and shea butter keep the skin supple and glowing.
Key ingredients: AHA, squalane, shea butter
An Amazon reviewer says: 'Bought KP butter. It's super high quality. Thick, moisturizing, great for dry skin. My son has eczema on his hands and it cleared it up fast. I want several tubes around the house and in my purse for easy access. The smell on the KP butter one is different, but not at all unpleasant.'
This lightweight lotion contains salicylic acid to unclog pores. Gentle enough for most skin types, it also contains soothing ingredients like chamomile and green tea to reduce redness and discomfort.
Key ingredients: Salicylic acid, vitamin E, chamomile
An Amazon reviewer says: 'I just tried this cream for the first time, and my arms are almost completely smooth after one use! My keratosis pilaris has been getting worse lately, but my usual exfoliation treatment wasn't helping as much as it used to. My arms are smooth for the first time in years and now I can stop wasting money on treatments that don't work. Very happy customer!!'
Known for working wonders on ingrown hairs, this water-like liquid helps clogged follicles clear up in no time. A thin layer post-shower or hair removal is all you need.
Key ingredients: Acetylsalicylic acid, glycerin
Amazon rating: 4.5/5 stars
An Amazon reviewer says: 'I have a sensitive skin and thick hair, and keratosis pilaris on top of that. My thighs and underarms used to look like a battlefield after shaving (I have to shave, since I'm trying at home IPL), that is, until I discovered this product. I've tried glycolic acid, medicinal ointments, fur oil, you name it. Nothing. Then I started using this product and it didn't seem to make a difference, but since I've decided to give 2 weeks to every product before discarding it, I've waited and I AM SO GLAD I DID. I use it 3x, instead of 2, on a clean dry skin. I has improved my condition so much! It does dry the skin, but people, there has to me something. Just moisturize heavily and you will be fine.'
Exfoliation is key to keeping KP at bay, but don't skip moisturizer. After showering, use this rich cream that's packed with soothing urea to protect and gently reduce any clogged skin.
Key ingredient: Urea
An Amazon reviewer says: 'I have tried hundreds of body lotions and none ever compared to this one. I am 58-years-old and have used body lotions (upon my mother's advice) since I was 15 years old. When I was young, most lotions did fine. As I aged, fewer and fewer were helpful. After age 50, I started trying expensive luxury creams and dermatologist endorsed brands, but none were working more than 6 hours a day—even with the regular exfoliating I do. I have no idea why I decided to try Eucerin (with 10% urea); I am so glad I did. It makes my skin feel moisturized and bouncy over 24 hours. Scaly and crepey skin is gone. I don't know how many years this will help my aging skin, but I have never found any other lotion or cream that comes close.'
This in-shower treatment has super-fine pieces of sodium palmate and magnesium oxide to gently treat ingrown hairs, keratosis pilaris, scarring, and acne. Plus, it smells like citrus to provide a pleasant sensorial experience.
Key ingredients: Sodium palmate, magniusm oxide exfoliants
An Amazon reviewer says: 'Body acne and scars and more...This stuff has made it all disappear and is smoothing out my skin. brightening it up and healing it, too. Wish I had this my whole life! Buy it!'
As a leading publisher of fashion, lifestyle, and beauty content, ELLE.com is committed to highlighting the best products in various categories by personally testing the latest and most innovative products, interviewing countless experts, and vetting customer-loved items. For this piece, ELLE.com editors spoke with skin experts to find the best products for treating KP or strawberry skin. The authors personally tested a number of these products and scoured reviews for the top-rated products on the market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
21 minutes ago
- Forbes
The Best 4 Healthcare Stocks To Buy Now In A Growing Sector
The relatively high dividends paid by some of these companies may prove worth the uncertain revenue ... More impact of Medicaid cuts. The healthcare sector is one of the largest in the U.S., with spending expected to account for 20% of the American economy as it reaches $5.2 trillion in 2025, according to NerdWallet. But the healthcare sector is likely to suffer considerably in the wake of the passage into law of the so-called Big Beautiful Bill. The industry's pain will result from a roughly $1 trillion reduction in Medicaid spending through 2034, according to the Congressional Budget Office. These cuts are likely to cause widespread pain. For example, 15.9 million Americans could lose Medicaid coverage, according to the Urban Institute. Hospitals' expenses for Medicaid patients could fall by $37 billion, estimated the Commonwealth Fund; to offset the lower revenue, hospitals, nursing homes, and doctors' offices could eliminate 477,000 jobs, according to the American Association of Medical Colleges. And many rural hospitals may be forced to close, forcing patients to travel further for care, noted the American Hospital Association. Nevertheless, the growth of companies providing high-value solutions to painful problems whose business models are relatively impervious to Medicaid cuts could provide attractive opportunities for investors. 4 Top Healthcare Stocks to Buy Now Healthcare consists of interconnected industries including the following: From this sector, the following stocks stand out. 1. Cardinal Health (CAH) Dublin, Ohio-based Cardinal Health distributes pharmaceuticals and medical products to more than 100,000 locations – controlling roughly 50% share of the market. Cardinal Health's stock rise can be attributed to a 2% boost, to $8.18, in analysts' 2025 consensus earnings per share due to stronger-than-expected growth and profitability in the company's pharmaceutical distribution and medical products segments, according to AInvest. Moreover, the stock could rise should the company report better than expected second quarter 2025 earnings. Due to Cardinal Health's 'cost discipline, supply chain stability, and rising demand for healthcare services post-pandemic,' analysts anticipate the company will report EPS of $2.04 – two cents above the Zacks consensus. Cardinal Health is on my list because investors have recognized the company is improving its operations, and many anticipate the company will exceed investor expectations. If demand remains strong and profitability rises, its shares could rise more. Medicaid cuts pose a significant risk to the healthcare sector, including Cardinal Health. Yet the company's diversified business model could enable it to withstand the worst damage from these cuts, AInvest reports. 2. Cencora (COR) Conshohocken, Pennsylvania-based Cencora – formerly known as AmerisourceBergen – is a drug wholesaler and contract research organization. Cencora's stock rise is likely due to the company's faster than expected growth in the first quarter of 2025. This growth resulted from higher unit volume, a boost in demand for diabetes and weight loss drugs, and a 2% increase, to $15.83, in the company's fiscal year 2025 earnings per share guidance, according to StockTwits. Although the pharmaceuticals distribution industry is intensely competitive, Cencora is expected to deliver solid profit growth and to exceed investor expectations. Specifically, investors anticipate the company's profits will rise 12.8% over the next five years in the wake of delivering 6% better than expected EPS for each of 'the trailing four quarters,' noted Zacks. I included Cencora due to its track record of beating investor expectations. However, Medicaid cuts could reduce drug sales as millions of Americans lose their Medicaid coverage – thus cutting into Cencora's revenues, noted AInvest. However, the company's focus on growing areas like specialty pharmaceuticals and its acquisition of a retinal care company could help offset the likely negative effects of Medicaid policy changes, according to Zacks. 3. Hinge Health (HNGE) San Francisco-based Hinge Health develops healthcare software for musculoskeletal care, acute injury, chronic pain and post-surgical rehabilitation. The company's stock market rise flowed from its torrid revenue growth – up 420% in the quarter ending in March, according to Google Finance. Hinge Health stock rose 23% after the company's May 2025 initial public offering. The stock is propelled by strong investor confidence in the company's digital musculoskeletal care platform and positive financial performance, according to BusinessInsider. Hinge Health is on my list for these same reasons. What's more, since the company primarily targets self-insured employers and is partnering with major health plans to expand into the Medicare Advantage market, this diversification could mitigate the pain of Medicaid cuts, noted AlphaSense. Nevertheless, Hinge Heath's stock price will likely rise only if the company beats expectations and raises guidance when the company next reports quarterly earnings. 4. Gilead Sciences (GILD) Foster City, California-based Gilead Sciences researches and develops antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza and COVID-19. Gilead's stock rise resulted from expectations-beating earnings in the first quarter, coupled with an optimistic forecast for 2025 EPS due to strong sales of existing products and new treatments, according to Reuters. In addition, the company's 99.9% effective HIV drug Sunienca received regulatory approval in the U.S. and Europe. Gilead is on my list because of its strong growth and bright prospects. However, since about 25% of the company's revenue is exposed to Medicaid – notably to its HIV drug Biktarvy – the Medicaid cuts could reduce the company's total revenue by 1% to 2%, according to Fierce Pharma. Bottom Line Healthcare is a huge, complex industry. Medicaid cuts could take a sizable bite out of many industry participants' revenue. The four companies described above – Cardinal Health, Cencora, Hinge Health, and Gilead – are likely more impervious to these cuts than owners of hospitals – particularly rural ones. Investors should scrutinize whether the relatively high dividends paid by some of these companies are worth the uncertain revenue impact of the Medicaid cuts.
Fast Company
an hour ago
- Fast Company
Finally: A malaria drug made just for babies has been approved – here's why it matters
The first ever treatment for malaria in young babies and infants has been approved. On Tuesday, Novartis announced it had received approval for the treatment, Coartem Baby (known as Riamet Baby in some countries) in Switzerland. Eight African countries, who participated in the assessment, are also expected to quickly approve the treatment. Novartis worked in collaboration with the Medicines for Malaria Venture (MMV), a Swiss-based nonprofit which works to prevent and develop treatments for the mosquito-borne disease, on the drug. Until now, malaria treatments have only been tested in children at least six months old and no drug had not been an approved malaria treatment for infants under 9.9 pounds (4.5 kilograms). And, because there had been no drug designed specifically for babies and small children, treatment has involved the very young taking treatments designed for more developed bodies. It also led to what Novatis called a 'treatment gap' for the age group. 'Together with our partners, we are proud to have gone further to develop the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve,' said Novartis CEO Vas Narasimhan in a press release. Narasimham continued, 'For more than three decades, we have stayed the course in the fight against malaria, working relentlessly to deliver scientific breakthroughs where they are needed most. Together with our partners, we are proud to have gone further to develop the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve.' According to Novartis, infection rates in Africa range from 3.4% and 18.4% in infants younger than six months old. In 2023, malaria caused around 597,000 deaths, most of which were in Africa, per The World Health Organization. Three quarters (76%) of those deaths were in children under the age of five. Martin Fitchet, CEO of MMV said in the press release, 'Malaria is one of the world's deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated.' Fitchet continued, 'The approval of Coartem Baby provides a necessary medicine with an optimised dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.' In recent years, malaria vaccine development has been accelerated. Still, there have been significant financial, logistical, and social hurdles, in deployment to the most vulnerable. However, Novartis says it plans to introduce its drug on a largely not-for-profit basis in order to help hard-hit 'endemic' areas fight the illness.
The Hill
an hour ago
- The Hill
St. Jude Children's Hospital's fundraising arm selects new CEO in midst of global expansion
St. Jude Children's Research Hospital's fundraising organization, ALSAC, promoted Ike Anand Tuesday to become its new president and chief executive officer. The leadership change comes as ALSAC — which raised more than $2.5 billion for the Memphis-based hospital in 2024, according to tax filings – navigates a global expansion and an increasingly complicated funding landscape in the United States. 'My role is to make sure that ALSAC is able to deliver on its promises to St. Jude so that St. Jude can continue to dream big,' said Anand, who had been ALSAC's chief operating officer since 2020. 'And ALSAC has a lot of initiatives in the pipeline to make sure that that happens.' Dr. Frederick M. Azar, chairman of ALSAC's board of directors, said Anand had been instrumental in redefining the organization's strategic direction, including its six-year $12.9 billion plan to provide pediatric cancer cures and treatments globally, and will help it continue to grow. 'Throughout his tenure, Ike has demonstrated visionary leadership and an unwavering commitment to the St. Jude mission,' Azar said in a statement. For Anand, who spent 15 years at travel tech firm Expedia Group and the rest of his career at other for-profit businesses, heading a nonprofit, even one as large and influential as ALSAC, was not an early life goal. But the COVID-19 pandemic and its impact on his family and friends changed that. 'I was hunting to do something that makes me feel valuable and purpose-driven in this world,' Anand said. 'And what I found, it was the perfect match.' At Expedia, he learned the importance of data, nurturing customer relationships, and managing teams around the world – experiences he says helps at ALSAC. 'We have a culture here now of testing and learning, getting better at what we do and ultimately understanding that we're not really competing against anybody else,' he said. 'We are trying to be better at what we do.' One area where Anand has drawn attention is incorporating artificial intelligence into ALSAC's fundraising. Its initiative of using AI to help guide its communications with donors has influenced multiple programs in philanthropy. Anand is quick to point out that ALSAC does not use donors' specific data to communicate to them individually, but does use aggregated data to make decisions about what information may interest certain types of donors. 'For us, it is really, really vital that the consumers have trust in us and that they see us valuing their privacy, that they see us valuing their information and using it in the right manner,' he said. 'And so we're really careful about it.' Health care policy changes from President Donald Trump's administration may impact rural hospitals and increase the need for St. Jude's services, which include free treatment for children with cancer. However, Anand says that St. Jude and ALSAC see it as their mission to care for all 400,000 children around the world diagnosed with cancer, so the changes do not really change their focus. 'Our mission is a unifying mission,' he said. 'We are not a political organization. I think everybody agrees that saving children is one of the most important things we can do as humanity.' Marlo Thomas, National Outreach Director for St. Jude and daughter of the late entertainer and philanthropist Danny Thomas who founded ALSAC and St. Jude, said that goal has remained the same. 'When my father founded St. Jude with a dream that no child should die in the dawn of life, he meant no child anywhere,' she said in a statement. 'Ike Anand is the perfect person to carry that dream forward and help continue to expand our mission globally.' ____ Associated Press coverage of philanthropy and nonprofits receives support through the AP's collaboration with The Conversation US, with funding from Lilly Endowment Inc. The AP is solely responsible for this content. For all of AP's philanthropy coverage, visit
